Template:Factor Xa Inhibitor Reversal: Difference between revisions
Mrosen5506 (talk | contribs) |
|||
| Line 14: | Line 14: | ||
| [[Edoxaban]] (Savaysa®)||10-14 hrs (longer in renal impairment)||~ 25%||As above | | [[Edoxaban]] (Savaysa®)||10-14 hrs (longer in renal impairment)||~ 25%||As above | ||
|- | |- | ||
| [[Rivaroxaban reversal|Rivaroxaban]] (Xarelto®)||9-13 hrs (longer in renal impairment)||No||As above | | [[Rivaroxaban reversal|Rivaroxaban]]<ref>Xarelto prescribing information. Titusville, NJ: Janssen Pharmaceuticals, Inc.; December 2014.</ref> (Xarelto®)||9-13 hrs (longer in renal impairment)||No||As above | ||
|- | |- | ||
| [[Fondaparinux]] (Arixtra®)||17-21 hrs (significantly longer in renal impairment)||No||4-factor [[PCC]] (Kcentra™)^ 50 units/kg—max 5000 units | | [[Fondaparinux]] (Arixtra®)||17-21 hrs (significantly longer in renal impairment)||No||4-factor [[PCC]] (Kcentra™)^ 50 units/kg—max 5000 units | ||
Revision as of 23:12, 6 January 2020
Factor Xa Inhibitor Reversal
| Anticoagulant | Half-life | Removed by HD | Strategies to reverse or minimize anticoagulant effects |
| Apixaban (Eliquis®) | 8-15 hrs (longer in renal impairment) | No |
|
| Edoxaban (Savaysa®) | 10-14 hrs (longer in renal impairment) | ~ 25% | As above |
| Rivaroxaban[1] (Xarelto®) | 9-13 hrs (longer in renal impairment) | No | As above |
| Fondaparinux (Arixtra®) | 17-21 hrs (significantly longer in renal impairment) | No | 4-factor PCC (Kcentra™)^ 50 units/kg—max 5000 units |
^Off-label
Andexanet alfa
FDA approved in May 2018, limited availability June 2018
Low Dose
400 mg IV bolus at rate of ~30 mg/minute, followed 2 minutes later by 4 mg/minute for up to 120 minutes
High Dose
800 mg IV bolus at rate of ~30 mg/minute, followed 2 minutes later by 8 mg/minute for up to 120 minutes
- ↑ Xarelto prescribing information. Titusville, NJ: Janssen Pharmaceuticals, Inc.; December 2014.